Table 1.
Summary features of the assessed individuals. Clinical and demographic characteristics of MS patients stratified by therapy (FTY, DMF, or NAT), left untreated (UNTR), and healthy controls (CT) that received SARS-CoV2 vaccination.
| Spike B panel | Sample size | Age in yrs, median (min-max) | Disease duration in yrs, median (min-max) | EDSS median (min-max) |
% females | |||
|---|---|---|---|---|---|---|---|---|
| T0 | T1 | T2 | T3 | |||||
| FTY | 11 | 18 | 17 | 24 | 45 (30-67) | 22 (10-50) | 2 (0-6.5) | 80 |
| DMF | 19 | 19 | 17 | 23 | 48 (27-63) | 18 (6-44) | 2.5 (0-6) | 74 |
| NAT | 15 | 12 | 18 | 20 | 43 (22-59) | 12 (2-39) | 1.5 (0-6) | 80 |
| UNTR | 8 | 11 | 3 | 12 | 55 (36-79) | 24 (1-60) | 2 (0-9.5) | 92 |
| CT | 7 | 28 | 7 | 32 | 51 (29-63) | na | na | 79 |
| B-T panel | Basal sample size | Stimulated sample size | ||||||
| T0 | T1 | T2 | T3 | T0 | T1 | T2 | T3 | |
| FTY | 8 | 12 | 12 | 16 | 10 | 13 | 17 | 17 |
| DMF | 13 | 15 | 12 | 22 | 15 | 18 | 13 | 22 |
| NAT | 15 | 12 | 18 | 20 | 15 | 11 | 18 | 20 |
| UNTR | 7 | 9 | 3 | 12 | 7 | 10 | 3 | 12 |
| CT | 7 | 25 | 7 | 28 | 7 | 25 | 7 | 29 |
| Cytokines | Basal sample size | Stimulated sample size | ||||||
| T0 | T1 | T2 | T3 | T0 | T1 | T2 | T3 | |
| FTY | na | na | na | 11 | na | na | na | 13 |
| DMF | na | na | na | 21 | na | na | na | 22 |
| NAT | na | na | na | 18 | na | na | na | 19 |
| UNTR | na | na | na | 10 | na | na | na | 9 |
| CT | na | na | na | 24 | na | na | na | 24 |
The number of individuals evaluated at each time point (T0, T1, T2, T3) is detailed at the basal level and after stimulation. Age refers to T3. EDSS, Expanded Disability Status Scale; na, not applicable.